Skip to main content

Advertisement

SpringerLink
Log in

In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole againstAspergillus species

  • New Antimicrobial Agents
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Twenty isolates of aspergillus were tested against saperconazole and 16 of these against itraconazole and amphotericin B using a macrodilution broth method. For 18 (90 %) of 20isolates tested against saperconazole, MICs were ≤3.1 mg/l and for 15 (75 %) of 20 isolates MFCs were ≤3.1 mg/l. For 9 (56 %) of 16 isolates tested against itraconazole, MICs were ≤3.1 mg/l, and for 4 (33 %) of 12 isolates MFCs were ≤3.1 mg/l. For all 16 isolates tested against amphotericin B MICs and MFCs were ≤4.0 mg/l; for 11 of 16 isolates MICs were ≤2.0 mg/l. Saperconazole appears to be highly active againstAspergillus spp. in vitro, with a bimodal distribution of MICs and MFCs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Denning DW, Tucker RM, Hanson LH, Stevens DA Treatment of invasive aspergillosis with itraconazole. American Journal of Medicine 1989, 86: 791–800.

    PubMed  Google Scholar 

  2. Van Cutsem J, Van Gerven F, Van De Ven M, Borgers M, Janssen PAJ Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrobial Agents and Chemotherapy 1984, 26: 527–534.

    PubMed  Google Scholar 

  3. Van Cutsem J, Van Gerven F, Janssen PAJ Oral and parenteral therapy with saperconazole (R66905) of invasive aspergillosis in normal and immunocompromised animals. Antimicrobial Agents and Chemotherapy 1989, 33: 2063–2068.

    PubMed  Google Scholar 

  4. Swatek F, Halde C, Rinaldi MJ, Shadomy HJ Aspergillus species and other opportunistic saprophytic hyaline hyphomycetes. In: Lennette EK, Balows A, Hausler WJ, Shadomy HJ (ed): Manual of clinical microbiology. American Society for Microbiology, Washington, DC, 1985, p. 584–594.

    Google Scholar 

  5. Lefler E, Stevens DA Inhibition and killing ofCandida albicans in vitro by five imidazoles in clinical use. Antimicrobial Agents and Chemotherapy 1984, 25: 450–454.

    PubMed  Google Scholar 

  6. Odds FC Antifungal activity of saperconazole (R66905) in vitro. Journal of Antimicrobial Chemotherapy 1989, 24: 533–537.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Medicine, Santa Clara Valley Medical Center, 751 South Bascom Ave., 95128, San Jose, California, USA

    D. W. Denning, L. H. Hanson & D. A. Stevens

  2. California Institute for Medical Research, 95128, San Jose, California, USA

    D. W. Denning, L. H. Hanson & D. A. Stevens

  3. Division of Infectious Diseases, Department of Medicine, Stanford University School of Medicine, 94305, Stanford, California, USA

    D. W. Denning & D. A. Stevens

Authors
  1. D. W. Denning
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. H. Hanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. A. Stevens
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Denning, D.W., Hanson, L.H. & Stevens, D.A. In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole againstAspergillus species. Eur. J. Clin. Microbiol. Infect. Dis. 9, 693–697 (1990). https://doi.org/10.1007/BF01964275

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01964275

Keywords

Search

Navigation